GOODWILL AND INTANGIBLE ASSETS

12 Months Ended

Dec. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND INTANGIBLE ASSETS

NOTE 4 – GOODWILL AND INTANGIBLE ASSETS

Goodwill

The Company completed the Merger, which gave rise to Goodwill of $4,879,999. Further, the Company added goodwill of $16,182,456 upon the completion of the PointR Merger. In general, goodwill is tested on an annual impairment date of December 31. However, since both assets are currently being developed for various cancer and COVID-19 therapies, the Company does not believe the there are any factors or indications that the goodwill is impaired.

Intangible Assets

In April 2018, Oncotelic Inc. entered into an Assignment and Assumption Agreement (the “Assignment Agreement”) with Autotelic Inc., an affiliate company, and Autotelic LLC, an affiliate company, pursuant to which Oncotelic acquired the rights to all intellectual property (“IP”) related to a patented product. As consideration for the Assignment Agreement, Oncotelic Inc. issued 204,798 shares of its Common Stock for a value of $819,191. The Assignment Agreement also provides that Oncotelic Inc. shall be responsible for all costs related to the IP, including development and maintenance, going forward.

The following table summarizes the balances as of December 31, 2021 and 2020, respectively, of the intangible assets acquired, their useful life, and annual amortization:

	December 31, 2021			Remaining Estimated Useful Life (Years)
Intangible asset – Intellectual Property	$	819,191			17.00
Intangible asset – Capitalization of license cost		190,989			17.00
		1,010,180
Less Accumulated Amortization		(188,339	)
Total	$	821,841

	December 31, 2020			Remaining Estimated Useful Life (Years)
Intangible asset – Intellectual Property	$	819,191			18.00
Intangible asset – Capitalization of license cost		190,989			18.00
		1,010,180
Less Accumulated Amortization		(136,974	)
Total	$	873,206

Amortization of identifiable intangible assets for the year ended December 31, 2021 and 2020 was $51,365 and $51,366, respectively.

The future yearly amortization expense over the next five years and thereafter are as follows:

For the years ended December 31,
2022		51,365
2023		51,365
2024		51,365
2025		51,365
2026		51,365
Thereafter		565,016
	$	821,841

In-Process Research & Development (“IPR&D”) Summary

The IPR&D assets were acquired in the PointR Merger during the year ended December 31, 2019. Since January 2021, the Company has determined that the IPR&D should be reported as an indefinitely lived asset and therefore will evaluate, on an annual basis, for any impairment on the IPR&D and will record an impairment if identified. The balance of IPR&D as of December 31, 2021 and December 31, 2020 was $1,101,760.

The following table summarizes the balances as of December 31, 2021 and 2020 of the IPR&D assets acquired in the PointR acquisition during the year ended December 31, 2019. The Company evaluates, on an annual basis, for any impairment and records an impairment if identified. The Company identified no impairment to IPR&D assets during its evaluation.

	December 31, 2021
Intangible asset – Intellectual Property	$	1,377,200
		1,377,200
Less Accumulated Amortization		(275,440	)
Total	$	1,101,760

	December 31, 2020
Intangible asset – Intellectual Property	$	1,377,200
		1,377,200
Less Accumulated Amortization		(275,440	)
Total	$	1,101,760